GlassScriptPhysician profile
Gourab Das
NPI 1487066965
$3,547.16
in general payments reported to CMS, 2019-2025
31 companies · $663 in 2025
The $663 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,178 · 2022: $553 · 2023: $566 · 2024: $587 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,816.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $717.87 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $703.04 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $298.78 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Pfizer INC. | $232.62 | 2021-2025 | |
| Novo Nordisk INC | $218.02 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $143.40 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $137.96 | 2021 | |
| Lilly USA, LLC | $128.61 | 2021-2024 | Mounjaro, Zepbound |
| Amgen INC. | $91.05 | 2021-2022 | |
| Eisai INC. | $90.43 | 2021 | |
| Amarin Pharma, INC. | $81.75 | 2021 | |
| Idorsia Pharmaceuticals US INC | $64.07 | 2022-2024 | Quviviq |
| Sanofi-Aventis U.S. LLC | $57.46 | 2024 | |
| Philips North America LLC | $53.93 | 2024-2025 | (5044) Mcot, (Ck7) Extended Holter, Extended Holter |
| Almatica Pharma LLC | $52.40 | 2023 | Loreev Xr, Gralise |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $52.09 | 2023-2025 | Seglentis, Zoryve, Livalo |
| Biohaven Pharmaceutical Holding Company LTD. | $48.18 | 2022 | |
| Boston Scientific Corporation | $46.66 | 2025 | Wavewriter Alpha Prime 16 |
| Merck Sharp & Dohme LLC | $46.56 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $41.54 | 2022-2023 | Crysvita |
| Janssen Pharmaceuticals, INC | $40.68 | 2021-2023 | Xarelto |
| Abiomed | $27.23 | 2025 | |
| Abbott Laboratories | $22.64 | 2024 | Octrode |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.11 | 2024 | |
| Nevro Corp. | $20.31 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.78 | 2022 | |
| Cipher Pharmaceuticals US LLC | $18.80 | 2025 | Spinosad, Natroba |
| Tms Neurohealth Centers INC. | $18.33 | 2025 | Tms Neurohealth Centers INC. |
| Inspire Medical Systems, INC. | $18.14 | 2025 | Inspire |
| Hologic Sales and Service, LLC | $17.86 | 2025 | Aptima |
| Acella Pharmaceuticals, LLC | $14.86 | 2024 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gourab Das listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.